Table 1.
Seroconversion and seroreversion rates for models based on AMA1, CelTOS and CSP
| Antigen | Month of survey | Number of subjects (N = 882) | Seroconversion rate (95% CI) | Seroreversion rate (95% CI) |
|---|---|---|---|---|
| AMA1 |
February |
294 |
0.144 (0.089, 0.235) |
0.131 (0.057, 0.302) |
| |
May |
294 |
0.074 (0.051, 0.108) |
0.005 (0.000, 51.872) |
| |
August |
294 |
0.078 (0.051, 0.118) |
0.034 (0.005, 0.223) |
|
§Total (AMA1) |
|
|
0.095 (0.070, 0.129) |
0.055 (0.022, 0.135) |
| CelTOS |
February |
294 |
0.026 (0.013, 0.054) |
0.057 (0.005, 0.609) |
| |
May |
294 |
0.027 (0.012, 0.059) |
0.079 (0.010, 0.617) |
| |
August |
294 |
0.020 (0.015, 0.027) |
0.0000002 (0.00, 4718.9) |
|
§Total (CelTOS) |
|
|
0.023 (0.013, 0.041) |
0.036 (0.002, 0.552) |
| CSP |
February |
294 |
λ1 = 0.226 (0.073, 1.700) |
0.171 (0.093, 0.311) |
| |
|
*LRT: P < 0.01 |
λ2 = 0.022 (0.012, 0.040) |
|
| |
May |
294 |
0.033 (0.014, 0.077) |
0.132 (0.029, 0.595) |
| |
August |
294 |
0.028 (0.014, 0.055) |
0.054 (0.006, 0.512) |
|
§Total (CSP) |
*LRT: P < 0.01 |
λ1 = 0.319 (0.084, 1.219) |
0.278 (0.166, 0.464) |
|
| λ2 = 0.024 (0.013, 0.044) | ||||
Seroconversion and seroreversion rates are estimated from seroprevalence curves for each antigen (Figures 3 and 4).
§Reversible catalytic model with standard error adjusted for clusters due to repeated cross-sectional sampling.
*LRT represents likelihood ratio test of no change in seroconversion rate.